Norges Bank Takes $36.95 Million Position in Prestige Consumer Healthcare Inc. $PBH

Norges Bank bought a new stake in shares of Prestige Consumer Healthcare Inc. (NYSE:PBH) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm bought 599,024 shares of the company’s stock, valued at approximately $36,954,000. Norges Bank owned 1.27% of Prestige Consumer Healthcare as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. Bayforest Capital Ltd acquired a new stake in Prestige Consumer Healthcare in the 4th quarter valued at $29,000. Barrow Hanley Mewhinney & Strauss LLC grew its stake in Prestige Consumer Healthcare by 106.8% in the 3rd quarter. Barrow Hanley Mewhinney & Strauss LLC now owns 548 shares of the company’s stock valued at $34,000 after acquiring an additional 283 shares during the period. Torren Management LLC acquired a new stake in Prestige Consumer Healthcare in the 4th quarter valued at $35,000. Danske Bank A S acquired a new stake in Prestige Consumer Healthcare in the 3rd quarter valued at $37,000. Finally, Hantz Financial Services Inc. boosted its holdings in Prestige Consumer Healthcare by 373.6% in the 3rd quarter. Hantz Financial Services Inc. now owns 682 shares of the company’s stock worth $43,000 after buying an additional 538 shares during the last quarter. 99.95% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Prestige Consumer Healthcare

In other news, VP Jeffrey Zerillo sold 1,207 shares of the business’s stock in a transaction dated Tuesday, May 5th. The shares were sold at an average price of $54.99, for a total transaction of $66,372.93. Following the transaction, the vice president owned 42,820 shares of the company’s stock, valued at approximately $2,354,671.80. The trade was a 2.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Insiders own 1.40% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on PBH shares. Weiss Ratings cut Prestige Consumer Healthcare from a “hold (c)” rating to a “hold (c-)” rating in a report on Thursday, May 14th. Canaccord Genuity Group lowered their price objective on Prestige Consumer Healthcare from $86.00 to $72.00 and set a “buy” rating on the stock in a report on Friday, May 15th. Zacks Research cut Prestige Consumer Healthcare from a “hold” rating to a “strong sell” rating in a report on Monday, May 18th. Finally, Oppenheimer cut Prestige Consumer Healthcare from an “outperform” rating to a “market perform” rating in a report on Thursday, May 14th. Two analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare currently has an average rating of “Hold” and an average target price of $70.75.

Prestige Consumer Healthcare Trading Up 1.1%

Shares of Prestige Consumer Healthcare stock opened at $47.69 on Tuesday. The stock has a market cap of $2.26 billion, a P/E ratio of 12.20, a P/E/G ratio of 1.52 and a beta of 0.35. The stock’s 50 day simple moving average is $52.82 and its 200-day simple moving average is $59.89. Prestige Consumer Healthcare Inc. has a 1-year low of $42.62 and a 1-year high of $87.12. The company has a debt-to-equity ratio of 0.54, a current ratio of 3.57 and a quick ratio of 2.25.

Prestige Consumer Healthcare (NYSE:PBH) last announced its quarterly earnings results on Wednesday, May 13th. The company reported $1.23 earnings per share for the quarter, missing the consensus estimate of $1.39 by ($0.16). The firm had revenue of $281.62 million for the quarter, compared to analyst estimates of $293.64 million. Prestige Consumer Healthcare had a net margin of 17.48% and a return on equity of 11.54%. The company’s revenue was down 5.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.32 EPS. Prestige Consumer Healthcare has set its FY 2027 guidance at 4.420-4.510 EPS. Analysts predict that Prestige Consumer Healthcare Inc. will post 4.45 EPS for the current fiscal year.

Prestige Consumer Healthcare Company Profile

Prestige Consumer Healthcare, Inc is a leading manufacturer and marketer of branded over-the-counter (OTC) healthcare products. The company focuses on developing, acquiring and commercializing a diverse portfolio of non-prescription remedies designed to address common consumer health needs, including pain relief, cold and cough, digestive health, eye care, skin care and women’s health.

Key brands in Prestige’s portfolio include Clear Eyes (eye health), Carmex (lip care), Chloraseptic (sore throat relief), Dramamine (motion sickness), Rolaids (antacid), Monistat (women’s health), BC Powder (pain relief), Little Remedies (pediatric cold and gas relief) and TheraTears (dry eye therapy).